Axsome Therapeutics AXSM Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$64.54M-126% | -$28.56M+39.5% | -$47.23M+1.6% | -$47.97M+19.3% | -$59.41M+20.7% | ||
| $116K+1.8% | $114K-5.0% | $120K0.0% | $120K-19.5% | $149K+15.5% | ||
| $23.44M+3.1% | $22.73M-1.6% | $23.1M-6.1% | $24.61M+5.6% | $23.31M+6.0% | ||
| $26.6M-4.9% | $27.96M— | $0-100% | $37.43M+93.0% | $19.4M+8.3% | ||
| $3.11M-14.6% | $3.64M-27.1% | $4.99M+181% | $1.78M+614% | $249K— | ||
| $41.17M— | —— | -$37.4M-727% | $5.97M-56.3% | $13.66M+76.4% | ||
| $17.23M+140% | $7.17M-86.8% | $54.25M+152% | $21.5M+2,529% | $818K-96.8% | ||
| $1.57M-2.2% | $1.61M0.0% | $1.61M+1.1% | $1.59M+1.1% | $1.57M-2.2% | ||
| -$608K— | —— | —— | —— | $208K+297% | ||
| $159K-1.2% | $161K+1.9% | $158K-50.2% | $317K-52.5% | $667K-5.8% | ||
| -$20.7M-11.0% | -$18.65M— | $0+100% | -$32.42M+25.2% | -$43.38M-65.5% | ||
| $121K+70.4% | $71K+22.4% | $58K+346% | $13K-96.2% | $338K+1,027% | ||
| -$121K-70.4% | -$71K-22.4% | -$58K-346% | -$13K+96.2% | -$338K-1,027% | ||
| $70M0.0% | $70M0.0% | $70M— | —— | —— | ||
| $6.34M+11.8% | $5.68M-42.9% | $9.95M-69.5% | $32.63M+66.1% | $19.65M+19.7% | ||
| $672K+24.2% | $541K-18.5% | $664K+28.2% | $518K+29.2% | $401K+21.5% | ||
| $9.3M+791% | $1.04M+24.0% | $842K-5.2% | $888K-79.5% | $4.34M+714% | ||
| $2.99M-81.7% | $16.39M-23.0% | $21.27M-38.4% | $34.54M+18.0% | $29.27M+105% | ||
| -$17.83M— | —— | $22.26M— | —— | -$14.44M-20.5% | ||
| $2.93M-3.9% | $3.05M-5.2% | $3.22M-14.6% | $3.77M-17.9% | $4.59M-3.5% | ||
| $159K-1.2% | $161K+1.9% | $158K-50.2% | $317K-52.5% | $667K-5.8% | ||
| $1.57M-2.2% | $1.61M0.0% | $1.61M+1.1% | $1.59M+1.1% | $1.57M-2.2% | ||
| $590K+107% | -$9.07M-169% | $13.19M+263% | -$8.1M-636% | $1.51M-86.2% | ||
| $116K+1.8% | $114K-5.0% | $120K0.0% | $120K-19.5% | $149K+15.5% | ||
| —— | —— | —— | —— | $2.25M— | ||
| -$608K— | —— | —— | —— | $208K+297% | ||
| $17.23M+140% | $7.17M-86.8% | $54.25M+152% | $21.5M+2,529% | $818K-96.8% | ||
| $9.87M— | —— | $3.45M+943% | $331K-91.8% | $4.03M— | ||
| $844K+5.9% | $797K-2.4% | $817K-0.7% | $823K+35.1% | $609K+76.0% | ||
| $1.76M— | $0-100% | $1.94M-14.6% | $2.27M+137% | $955K-68.3% | ||
| $672K+24.2% | $541K-18.5% | $664K+28.2% | $518K+29.2% | $401K+21.5% | ||
| -$3.26M-10.8% | -$2.95M-17.5% | -$2.51M-13.8% | -$2.2M+3.6% | -$2.29M-7.2% | ||
| $95K-3.1% | $98K-48.1% | $189K-63.4% | $517K+31.6% | $393K+19.5% | ||
| $9.98M-34.9% | $15.34M-1.2% | $15.52M+33.1% | $11.66M-31.5% | $17.04M+1,384% | ||
| $679K+22.8% | $553K-19.2% | $684K+27.4% | $537K+30.3% | $412K+22.3% | ||
| $70M0.0% | $70M0.0% | $70M— | —— | —— | ||
| $3.43M+2,885% | $115K-94.3% | $2.04M+146% | $828K-46.0% | $1.53M+229% | ||
| —— | —— | —— | —— | $23.87M— | ||
| —— | —— | —— | —— | $7.6M— | ||
| -$20.82M-11.2% | -$18.72M— | $0+100% | -$32.44M+25.8% | -$43.71M-66.6% | ||
| -$20.82M-11.2% | -$18.72M— | $0+100% | -$32.44M+25.8% | -$43.71M-66.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Axsome Therapeutics generate?
- Axsome Therapeutics (AXSM) generated -$71.8M in operating cash flow over the trailing twelve months.
- What is Axsome Therapeutics's free cash flow?
- After $263.0K of capital expenditures, Axsome Therapeutics's free cash flow was -$72.0M over the trailing twelve months, up 39.4% year over year.
- Where does Axsome Therapeutics's cash flow data come from?
- Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
